anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The enhanced recovery after surgery (ERAS) pathway is designed to facilitate recovery after surgery by packaging evidence-based protocols specific to each aspect of the perioperative period, including the preoperative, intraoperative, postoperative, and post-discharge periods. The ERAS pathway, which was originally developed for use with colonic resection, is now being expanded to include a variety of surgical procedures, and the ERAS Society has published a consensus review of the ERAS pathway for head and neck surgery with free tissue transfer reconstruction (HNS-FTTR). The ERAS pathway for HNS-FTTR consists of various important protocols, including early postoperative mobilization, early postoperative enteral nutrition, abolition of preoperative fasting, preoperative enteral fluid loading, multimodal pain management, and prevention of postoperative nausea and vomiting. In recent years, meta-analyses investigating the utility of the ERAS pathway in head and neck cancer surgery have also been presented, and all reports showed that the length of the postoperative hospital stay was reduced by the implementation of the ERAS pathway. The ERAS pathway is now gaining traction in the field of head and neck surgery; however, the details of its efficacy remain uncertain. We believe the future direction will require research focused on improving the quality of postoperative patient recovery and patient satisfaction. It will be important to use patient-reported outcomes to determine whether the ERAS pathway is actually beneficial.
PURPOSE:To accomplish mass production of rat endoserine-matured peptide through transformed fungi or cells by synthesizing DNA containing such DNA as to code the rat endoserine containing a specific basic sequence. CONSTITUTION:Firstly, a transformant containing DNA coding the rat endoserine at least partly containing a basic sequence of the formula is formed. Thence, this transformant is put to culture to produce and accumulate matured rat endoserine in the resulting cultured product followed by collecting the matured rat endoserine, thus obtaining matured rat endoserine protein. The host for obtaining the above-mentioned transformant is e.g., Escherichia sp. or Bacillus sp. bacteria, yeast, animal cells. The rat endoserine-matured protein thus produced is useful for e.g., in particular, analyzing the mechanism of human blood vessel contraction.
The combination of aspirin plus a P2Y12 receptor inhibitor, also known as dual antiplatelet therapy (DAPT), is the cornerstone of treatment for patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI). However, a considerable number of patients undergoing PCI also have an indication to be on treatment with an oral anticoagulant (OAC). It is estimated that 10-15% of PCI patients also have an indication to be on OAC, raising concerns on their optimal antithrombotic treatment regimen. Studies have consistently shown dropping aspirin and maintaining a P2Y12 inhibitor and OAC to be associated with reduces bleeding without any significant increase in ischemic events. Accordingly, current practice recommendations is to limit the use of aspirin to the peri-PCI period and maintain dual therapy with a P2Y12 inhibitor and an OAC. Clopidogrel is the P2Y12 inhibitor of choice in PCI patients requiring OAC. However, concerns have been raised based on the notion that a considerable number of patients may have inadequate response to clopidogrel, also known as high platelet reactivity (HPR) status, and thus be at risk for thrombotic complications. Although practice recommendations indicate that the use of potent P2Y12 inhibitors (i.e., ticagrelor) may be considered in patients at increased thrombotic risk, they do not recommend routine testing to identify patients with HPR status. Nevertheless, consensus recommendations do indicate that the selective use of tests to define HPR status is a reasonable option in selected cases such as PCI patients requiring OAC. The aim of this study is to assess the pharmacodynamic effects of different P2Y12 inhibiting therapy (clopidogrel vs ticagrelor) in patients at high risk for HPR identified according to the ABCD-GENE score in PCI treated patients also requiring OAC. Up to a total of up to 63 patients are planned to be prospectively enrolled in this investigation which will entail a series of comprehensive pharmacodynamic assessments to reach the study aim.
A system and method for connecting a healthcare business to a plurality of laboratories. The system includes a client application which executes on a workstation, e.g., at a physician's office or other business. Using this application, a user may place a laboratory order for a patient. In one embodiment, the laboratory system may utilize a Global Master Patient Index (GMPI) for maintaining patient record information across multiple healthcare sites. Thus, this GMPI information may be used in retrieving the appropriate patient record. User input specifying general requisition information is received, such as contact information for the patient, guarantor information, billing information, etc. Billing information may also be received. If a requisition was previously created for the specified patient, relative information from that requisition may populate the appropriate user interface fields. User input specifying diagnosis codes for the requisition may also received. The user may enter a list of diagnosis codes, such as ICD-9 codes that specify the caregiver's diagnosis for the patient. The user may also enter a list of test codes specifying the desired lab tests to perform on the patient specimen(s). User input specifying a list of labs to whom to electronically send the requisition may also be received. In the preferred embodiment, the system is operable to send requisitions to a plurality of labs. User input specifying a list of caregivers to whom to electronically send the results of the lab tests may also be specified. User input specifying other information for the requisition may also be received, such as lab instructions, information regarding the patient specimens collected, etc. The requisition information may be stored, and the user may use a menu option to select and electronically send the requisitions, e.g., by interfacing a middleware server which interfaces with the system for each laboratory which receives the requisitions.
BACKGROUND: The association between obesity and some cardiovascular complications such as heart failure (HF) is well established, and drugs affecting adiposity are supposed to be promising treatments for these conditions. The sodium-glucose cotransporter-2 inhibitors (SGLT2i) are antidiabetic drugs showing benefits in patients with HF, despite the underlying mechanisms have not been completely understood yet. SGLT2i are supposed to promote systemic effects, such as triglycerides mobilization, through the enhancement of fibroblast growth factor-21 (FGF-21) activity. So, in this study, we evaluated the effects of dapagliflozin treatment on FGF-21 and related receptors (FGF-Rs) gene expression and on lipid content in myocardial tissue in an animal model of genetically induced obesity to unravel possible metabolic mechanisms accounting for the cardioprotection of SGLT2i.
METHODS: Six-week-old C57BL/6J wild-type mice and B6.V-LEP (ob/ob) mice were randomly assigned to the control or treatment group (14 animals/group). Treatment was based on the administration of dapagliflozin 0.15 mg/kg/day for 4 weeks. The gene expression of FGF-21 and related receptors (FGF-R1, FGF-R3, FGF-R4, and β-klotho co-receptor) was assessed at baseline and after treatment by real-time PCR. Similarly, cardiac triglycerides concentration was measured in the control group and treated animals.
RESULTS: At baseline, FGF-21 mRNA expression in the heart did not differ between lean and obese ob/ob mice. Dapagliflozin administration significantly increased heart FGF-21 gene expression, but only in ob/ob mice (p < 0.005). Consistently, when measuring the amount of triglycerides in the cardiac tissue, SGLT2i treatment reduced the lipid content in obese ob/ob mice, while no significant effects were observed in treated lean animals (p < 0.001). The overall expression of the FGF-21 receptors was only minimally affected by dapagliflozin treatment both in obese ob/ob mice and in lean controls.
CONCLUSIONS: Dapagliflozin administration increases FGF-21gene expression and reduces triglyceride content in myocardial tissue of ob/ob mice, while no significant effect was observed in lean controls. These results might help understand the cardiometabolic effects of SGLT2i inducing increased FGF-21 synthesis while reducing lipid content in cardiomyocytes as a possible expression of the switch to different energy substrates. This mechanism could represent a potential target of SGLT2i in obesity-related heart diseases.
The invention relates to Blackberrylily rhizome antiviral injection, preparation and venous medicine feeding blackberrylily rhizome antiviral injection thereof. The original medicine comprises 1-1000 portion of belamcanda rhizome by weight, 1-1000 portion of honeysuckle by weight, 1-1000 portion of Eupatorium by weight, 1-1000 portion of capilary artemisia by weight, 1-1000 portion of radix bupleuri by weight, 1-1000 portion of dandelion by weight, 1-1000 portion of isatis root by weight, 1-1000 portion of dyers woad leaf by weight. The medicine is obtained by following steps: distilling by vapor, boiling, adding adding clarifier, alcohol-settling, water-settling, centrifugation, hyperfiltration to get active component of the Blackberrylily rhizome antiviral injection, and then subpackaging, disinfecting to get finished preparation, in which the chlorogenic acid (C16H18O9) is not less than 0.5 mg/ml. The injection has the function of antivirus and killing bacteria and relieving inflammation and treating epidemic hemorrhagic fever early disease. The invention avoids the medicine liquid thickness, deposition and color changing, stabilizes the preparation, prolongs the product effective date. The injection can be applied through vein so as to prevent the adverse effects such as pain in the administration location, blood stasis and even muscle necrosis.
A packaged antiperspirant product is provided. The packaged antiperspirant product includes an anhydrous antiperspirant composition having from 40% to 60%, by weight of the anhydrous antiperspirant composition, of solids. The solids include an antiperspirant active, one or more waxes, and one or more fillers having a total concentration from about 15% to about 35% by weight of the anhydrous antiperspirant composition. The antiperspirant composition also has from about 35% to about 60%, by weight of the composition, of one or more carriers other than water, wherein the one or more carriers comprises a non-volatile silicone fluid. The package includes a container body having an interior chamber storing the anhydrous antiperspirant composition, a dome closing one end of the container body and having a plurality of apertures extending through the thickness of the dome. An elevator and feed screw are disposed within the container body.
Mucin overproduction is a common feature of chronic airway diseases such as asthma and chronic obstructive pulmonary disease (COPD), and exacerbates their underlying respiratory condition. Surfactant protein D (SP-D) protects against airway diseases through modulation of immune reactions, but whether it also exerts direct effects on airway epithelial cells has remained unclear. Therefore, we sought to investigate the inhibitory role of SP-D on mucin production in airway epithelial cells. We prepared air-liquid interface (ALI) cultures of human primary bronchial epithelial cells (HBECs), which recapitulated a well-differentiated human airway epithelium. Benzo(a)pyrene (BaP), a key toxicant in cigarette smoke, induced mucin 5AC (MUC5AC) production in ALI-cultured HBECs, airway secretory cell lines, and airway epithelia of mice. Then, the protective effects of SP-D against the BaP-induced mucin overproduction were examined. BaP increased MUC5AC production in ALI cultures of HBECs, and this effect was attenuated by SP-D. SP-D also suppressed the BaP-induced phosphorylation of extracellular signal-regulated kinase (ERK) and MUC5AC expression in NCI-H292 goblet-like cells, but not in NCI-H441 club-like cells. Signal regulatory protein α (SIRPα) was found to be expressed in HBECs and NCI-H292 cells but absent in NCI-H441 cells. In NCI-H292 cells, SP-D activated SH2 domain-containing tyrosine phosphatase-1 (SHP-1), downstream of SIRPα, and knockdown of SIRPα abolished the suppressive effects of SP-D on BaP-induced ERK phosphorylation and MUC5AC production. Consistent with these in vitro findings, intratracheal instillation of SP-D prevented the BaP-induced phosphorylation of ERK and Muc5ac expression in airway epithelial cells in a mouse model. SP-D acts directly on airway epithelial cells to inhibit mucin secretion through ligation of SIRPα and SHP-1-mediated dephosphorylation of ERK. Targeting of SIRPα is therefore a potential new therapeutic approach to suppression of mucin hypersecretion in chronic airway diseases such as COPD and asthma.
Anemia has occurred in NSAID-treated patients. This may be due to occult or gross blood loss, fluid retention, or an incompletely described effect on erythropoiesis. If a patient treated with NALFON has any signs or symptoms of anemia, monitor hemoglobin or hematocrit.

NSAIDs, including NALFON, may increase the risk of bleeding events. Co-morbid conditions such as coagulation disorders, concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. Monitor these patients for signs of bleeding [ see Drug Interactions ( 7) ].
Healthy subjects were given a single dose of placebo tablet(s) matched to the active treatment, subjects receiving placebo were equally distributed across dose groups. Tablet(s) were taken orally with 240 milliliter of water after an overnight fast of at least 10 hours.
The evolution and challenges of unicompartmental knee prostheses (UNIS) are addressed, highlighting their use since the 1970s as an alternative to osteotomies. Over the years, these prostheses have gained popularity, although they initially faced criticism due to higher revision rates compared to total knee arthroplasties (TKA). Multicenter studies, such as that of Heck et al., revealed an increase in failures associated with body mass index and female sex. Despite this, recent reviews, such as that of Vasso et al., have shown a positive evolution in the results of UNIS, although with a higher percentage of revisions than TKA. The importance of adequate patient selection, meticulous surgical technique, and avoidance of overcorrection for surgical success is also emphasized. It is mentioned that external UNIS, although representing a small percentage of total prosthetic knees, have shown favorable results in terms of long-term survival. In addition, technical aspects such as minimal bone resection and polyethylene wear, which are crucial for the performance of prostheses, are discussed. In conclusion, the need for further research and improvement of techniques to optimize the results of unicompartmental arthroplasties is highlighted.
The autonomic nervous system plays a key role in maintaining body hemostasis through both the sympathetic and parasympathetic nervous systems. Sympathetic overstimulation as a reflex to multiple pathologies, such as septic shock, brain injury, cardiogenic shock, and cardiac arrest, could be harmful and lead to autonomic and immunologic dysfunction. The continuous stimulation of the beta receptors on immune cells has an inhibitory effect on these cells and may lead to immunologic dysfunction through enhancing the production of anti-inflammatory cytokines, such as interleukin-10 (IL-10), and inhibiting the production of pro-inflammatory factors, such as interleukin-1B IL-1B and tissue necrotizing factor-alpha (TNF-alpha). Sympathetic overstimulation-induced autonomic dysfunction may also happen due to adrenergic receptor insensitivity or downregulation. Administering anti-adrenergic medication, such as beta-blockers, is a promising treatment to compensate against the undesired effects of adrenergic surge. Despite many misconceptions about beta-blockers, beta-blockers have shown a promising effect in decreasing mortality in patients with critical illness. In this review, we summarize the recently published articles that have discussed using beta-blockers as a promising treatment to decrease mortality in critically ill patients, such as patients with septic shock, traumatic brain injury, cardiogenic shock, acute decompensated heart failure, and electrical storm. We also discuss the potential pathophysiology of beta-blockers in various types of critical illness. More clinical trials are encouraged to evaluate the safety and effectiveness of beta-blockers in improving mortality among critically ill patients.
The Tritanium® Acetabular Shell, cleared for use under FDA 510(k) K081171, is a hemispherical acetabular shell with a 3D surface for biological fixation, fabricated from Commercially Pure Titanium (CPTi). The shell is built upon the design features and clinical history of the existing Trident® Tritanium®, Trident® AD, and Trident® HA hemispherical acetabular shells. The device is designed with a roughened surface and high coefficient of friction to resist micromotion and promote initial fixation. The Tritanium® Acetabular Shell, intended for use in a cementless application, is available in sizes from 44 millimeter (mm) through 66 mm and is compatible with Trident® polyethylene liners and acetabular screws. This advanced technology is designed to address the need for improved initial and biological fixation. Data in support of these marketing claims will be collected in the Tritanium® Primary Acetabular Shell Study.

A prospective, post-market, multi-center design will be employed. Radiographs will be assessed by an independent reviewer.

Cases will be enrolled at 7 to 12 centers. The enrollment goal ranges from 20 to 34 cases implanted with the Tritanium® Acetabular Shell per center. The enrollment goal range is dependent upon the number of participating centers as well as the relative rates of enrollment of the two treatment groups. Although a range is presented, there is no maximum limit to the number of cases that a center may enroll. In the event that a center far exceeds the overall enrollment goal or enrollment into one of the treatment groups is completed, Stryker may ask the center to cease enrollment so as not to skew the data. All participating centers will comply with the federal regulations regarding patient informed consent and Institutional Review Board (IRB) approval. Non-compliance of a study center may result in termination of the center's participation in the study.
Routine Information was given before undergoing MRI procedure and Anxiety was assessed within 20 minutes of Intervention. Assessment of Experience, Co-operation was done.
The invention relates to a washout traditional Chinese medicine for treating childhood eczema. The medicine is prepared from 10g of golden cypress, 18g of cortex dictam, 20g of radix angelicae, 22g of flavescen, 18g of sweet wormwood, 10g of borneol and 18g of radix sileris. The preparation method comprises the steps of taking all the materials except borneol, adding 1500ml of water, heating until boiling condition with high heat, boiling for 30 minutes with mild heat, skimming and filtering to prepare decoction, adding borneol in the decoction, stirring until the borneol fully dissolves, using the decoction to washing and scrubbing wounded parts, using three times per day. One week is one treatment course. The external applied medicine has the functions of clearing heat and drying dampness, dispelling wind and arresting itching, cooling blood and activating blood, has obvious curative effect to childhood eczema and pruritus due to damp heat. The washout traditional Chinese medicine has abundant sources of materials, low cost and is convenient to use.
Enrolling about 5,000 early-stage NSCLC patients from January 2018 to June 2024 across 25 centers in China, data including chest CT scans and clinicopathological parameters will be used to train and validate the AI model. Patients will be divided into "high-risk" and "low-risk" groups based on the model's risk score, and clinical benefits of treatments like lymph node dissection, adjuvant therapy, and SBRT will be analyzed.
CNAs in Aim 1 will participate in the standardized, 8-week Mindful Self-Compassion course. Each 8-week session will last for 2.5 hours. Also included is a half day retreat, that CNAs may attend if they are able.
BACKGROUND: Treatment of fatigue is important for many patients with multiple sclerosis (MS). While pharmacological options have not shown consistent benefit, psychological interventions offer another avenue of treatment. Cognitive behavioural therapy (CBT) involves strategies to change maladaptive cognition and illness behaviours that modulate how patients with MS respond to fatigue. The aim of this study was to perform a systematic review and meta-analysis to determine the effectiveness of CBT for the treatment of fatigue in patients with MS.
METHODS: Five databases (Cochrane Central Register of Controlled Trials, MEDLINE/PubMed, Embase, Emcare and PsycINFO) were searched up until 31 July 2023. Randomised controlled trials involving adult patients with MS and fatigue, comparing CBT with another intervention or usual treatment were included. Studies were required to measure fatigue severity and/or the impact of fatigue as the primary outcome(s). Each study was assessed for bias using the Cochrane Risk of Bias tool version 2. Studies with sufficient data were used for meta-analysis to quantify the short- and long-term effects of CBT on MS-related fatigue. The level of certainty provided by the body of evidence was evaluated using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) framework.
RESULTS: Eight studies were included in the review and six studies contributed to the meta-analysis. Most studies had a low overall risk of bias. CBT interventions differed in the number, duration and frequency of sessions, mode of delivery and therapist. There were significant short- (standardised mean difference (SMD) -0.58, 95% confidence interval (95%CI) -0.85 to -0.31, P-value < 0.0001) and long-term (SMD -0.36, 95%CI -0.52 to -0.19, P-value < 0.0001) effects supporting CBT. The evidence provided a low level of certainty for the short-term effect because of heterogeneity of results and possible publication bias, while there was high certainty for the long-term result.
CONCLUSION: The study provides secondary evidence that CBT has moderate short-term and small long-term effects in reducing fatigue in patients with MS. CBT should be regarded as a viable evidence-based intervention, particularly in the absence of established alternatives. Future research should identify the ideal characteristics of a fatigue-specific CBT intervention, patient factors that predict treatment response and strategies to maintain initial improvements over time.